Contineum Therapeutics, Inc. 4

Chief Scientific Officer Daniel S. Lorrain exercised 1,040 stock options at $1.01 and sold 1,040 Contineum Therapeutics Class A shares at $16.00 under a 10b5-1 plan.

On July 8 and 9, 2026, Contineum Therapeutics, Inc. Chief Scientific Officer Daniel S. Lorrain exercised previously granted stock options at $1.01 per share for a total of 1,040 shares of Class A Common Stock and immediately sold the same number of shares at $16.00 per share under a pre-arranged Rule 10b5-1 trading plan adopted on September 23, 2025. Specifically, he exercised 1,015 options and sold 1,015 shares on July 8, and exercised 25 options and sold 25 shares on July 9, generating gross sale proceeds of approximately $16,640 and realizing the spread between the option price and the market sale price. After these transactions, he directly owned 135,202 shares of Class A Common Stock, and his spouse indirectly owned an additional 10,110 shares, while the exercised options were fully vested and reduced the remaining option balances accordingly.

Filing Facts

CIK

1855175

Ticker

CTNM

Form

4

Source Type

fda

Accession

0001628280-26-047909

Alert Tier

5